307 related articles for article (PubMed ID: 30639242)
1. The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2.
Kovalski JR; Bhaduri A; Zehnder AM; Neela PH; Che Y; Wozniak GG; Khavari PA
Mol Cell; 2019 Feb; 73(4):830-844.e12. PubMed ID: 30639242
[TBL] [Abstract][Full Text] [Related]
2. Ras functional proximity proteomics establishes mTORC2 as new direct ras effector.
Kovalski JR; Shanderson RL; Khavari PA
Oncotarget; 2019 Aug; 10(50):5126-5135. PubMed ID: 31497244
[TBL] [Abstract][Full Text] [Related]
3. Direct physical interaction of active Ras with mSIN1 regulates mTORC2 signaling.
Lone MU; Miyan J; Asif M; Malik SA; Dubey P; Singh V; Singh K; Mitra K; Pandey D; Haq W; Amita H; Singh PK; Kiess W; Kaessner F; Garten A; Bhadauria S
BMC Cancer; 2019 Dec; 19(1):1236. PubMed ID: 31856761
[TBL] [Abstract][Full Text] [Related]
4. Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling.
Terrell EM; Durrant DE; Ritt DA; Sealover NE; Sheffels E; Spencer-Smith R; Esposito D; Zhou Y; Hancock JF; Kortum RL; Morrison DK
Mol Cell; 2019 Dec; 76(6):872-884.e5. PubMed ID: 31606273
[TBL] [Abstract][Full Text] [Related]
5. RAS-mediated oncogenic signaling pathways in human malignancies.
Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
[TBL] [Abstract][Full Text] [Related]
6. Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling.
Bossler F; Kuhn BJ; Günther T; Kraemer SJ; Khalkar P; Adrian S; Lohrey C; Holzer A; Shimobayashi M; Dürst M; Mayer A; Rösl F; Grundhoff A; Krijgsveld J; Hoppe-Seyler K; Hoppe-Seyler F
mBio; 2019 Feb; 10(1):. PubMed ID: 30755508
[TBL] [Abstract][Full Text] [Related]
7. Impact of Nrf2 on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells in vitro and in vivo.
Shao J; Glorieux C; Liao J; Chen P; Lu W; Liang Z; Wen S; Hu Y; Huang P
Free Radic Res; 2018 Jun; 52(6):661-671. PubMed ID: 29621903
[TBL] [Abstract][Full Text] [Related]
8. Ras-mediated activation of mTORC2 promotes breast epithelial cell migration and invasion.
Collins SE; Wiegand ME; Werner AN; Brown IN; Mundo MI; Swango DJ; Mouneimne G; Charest PG
Mol Biol Cell; 2023 Feb; 34(2):ar9. PubMed ID: 36542482
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-mediated reversion of oncogenic KRAS mutation results in increased proliferation and reveals independent roles of Ras and mTORC2 in the migration of A549 lung cancer cells.
Werner AN; Kumar AI; Charest PG
Mol Biol Cell; 2023 Dec; 34(13):ar128. PubMed ID: 37729017
[TBL] [Abstract][Full Text] [Related]
10. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
Counter C
Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
[TBL] [Abstract][Full Text] [Related]
11. RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity.
Castel P; Dharmaiah S; Sale MJ; Messing S; Rizzuto G; Cuevas-Navarro A; Cheng A; Trnka MJ; Urisman A; Esposito D; Simanshu DK; McCormick F
Proc Natl Acad Sci U S A; 2021 Aug; 118(33):. PubMed ID: 34380736
[TBL] [Abstract][Full Text] [Related]
12. A Proteomic approach for protein-profiling the oncogenic ras induced transformation (H-, K-, and N-Ras) in NIH/3T3 mouse embryonic fibroblasts.
Kim S; Lee YZ; Kim YS; Bahk YY
Proteomics; 2008 Aug; 8(15):3082-93. PubMed ID: 18601226
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic Screening Identifies Protein Synthesis Inhibitors as H-Ras-Nanocluster-Increasing Tumor Growth Inducers.
Najumudeen AK; Posada IM; Lectez B; Zhou Y; Landor SK; Fallarero A; Vuorela P; Hancock J; Abankwa D
Biochemistry; 2015 Dec; 54(49):7212-21. PubMed ID: 26568031
[TBL] [Abstract][Full Text] [Related]
14. PI3K/Akt promotes feedforward mTORC2 activation through IKKα.
Dan HC; Antonia RJ; Baldwin AS
Oncotarget; 2016 Apr; 7(16):21064-75. PubMed ID: 27027448
[TBL] [Abstract][Full Text] [Related]
15. MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling.
Xu K; Chen G; Li X; Wu X; Chang Z; Xu J; Zhu Y; Yin P; Liang X; Dong L
Sci Rep; 2017 Feb; 7():41718. PubMed ID: 28176801
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
Nussinov R; Tsai CJ; Jang H
Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic synergism between ErbB1, nucleolin, and mutant Ras.
Farin K; Schokoroy S; Haklai R; Cohen-Or I; Elad-Sfadia G; Reyes-Reyes ME; Bates PJ; Cox AD; Kloog Y; Pinkas-Kramarski R
Cancer Res; 2011 Mar; 71(6):2140-51. PubMed ID: 21257709
[TBL] [Abstract][Full Text] [Related]
18. The impact of oncogenic RAS on redox balance and implications for cancer development.
Lim JKM; Leprivier G
Cell Death Dis; 2019 Dec; 10(12):955. PubMed ID: 31852884
[TBL] [Abstract][Full Text] [Related]
19. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
20. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]